Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,359 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Persistent Expression of Recipient-type ABH Antigen after ABO-incompatible Allogeneic Hematopoietic Stem Cell Transplantation.
Misaki Y, Kako S, Kawamura S, Takeshita J, Yoshino N, Yoshimura K, Gomyo A, Akahoshi Y, Tamaki M, Kusuda M, Kameda K, Wada H, Kawamura K, Sato M, Terasako-Saito K, Kimura SI, Nakasone H, Kishino K, Muroi K, Kanda Y. Misaki Y, et al. Among authors: kanda y. Intern Med. 2022 Jun 15;61(12):1887-1890. doi: 10.2169/internalmedicine.8315-21. Epub 2021 Nov 20. Intern Med. 2022. PMID: 34803100 Free PMC article.
Limited efficacy of lamivudine against hepatitis B virus infection in allogeneic hematopoietic stem cell transplant recipients.
Ohnishi M, Kanda Y, Takeuchi T, Won Kim S, Hori A, Niiya H, Chizuka A, Nakai K, Saito T, Makimoto A, Tanosaki R, Watanabe T, Kobayashi Y, Tobinai K, Takaue Y, Mineishi S. Ohnishi M, et al. Among authors: kanda y. Transplantation. 2002 Mar 15;73(5):812-5. doi: 10.1097/00007890-200203150-00027. Transplantation. 2002. PMID: 11907433
Therapeutic potential of a reduced-intensity preparative regimen for allogeneic transplantation with cladribine, busulfan, and antithymocyte globulin against advanced/refractory acute leukemia/lymphoma.
Saito T, Kanda Y, Kami M, Kato K, Shoji N, Kanai S, Ohnishi T, Kawano Y, Nakai K, Ogasawara T, Matsubara H, Makimoto A, Tanosaki R, Tobinai K, Wakasugi H, Takaue Y, Mineishi S. Saito T, et al. Among authors: kanda y. Clin Cancer Res. 2002 Apr;8(4):1014-20. Clin Cancer Res. 2002. PMID: 11948108 Clinical Trial.
Impact of stem cell source and conditioning regimen on erythrocyte recovery kinetics after allogeneic haematopoietic stem cell transplantation from an ABO-incompatible donor.
Kanda Y, Tanosaki R, Nakai K, Saito T, Ohnishi M, Niiya H, Chizuka A, Yakushijin K, Urahama N, Ueda K, Iijima K, Ando T, Matsubara H, Kami M, Makimoto A, Kobayashi Y, Tobinai K, Mineishi S, Takaue Y. Kanda Y, et al. Br J Haematol. 2002 Jul;118(1):128-31. doi: 10.1046/j.1365-2141.2002.03693.x. Br J Haematol. 2002. PMID: 12100136 Free article.
Allogeneic hematopoietic stem cell transplantation from family members other than HLA-identical siblings over the last decade (1991-2000).
Kanda Y, Chiba S, Hirai H, Sakamaki H, Iseki T, Kodera Y, Karasuno T, Okamoto S, Hirabayashi N, Iwato K, Maruta A, Fujimori Y, Furukawa T, Mineishi S, Matsuo K, Hamajima N, Imamura M. Kanda Y, et al. Blood. 2003 Aug 15;102(4):1541-7. doi: 10.1182/blood-2003-02-0430. Epub 2003 Apr 24. Blood. 2003. PMID: 12714500 Free article.
Pharmacokinetics of alemtuzumab after haploidentical HLA-mismatched hematopoietic stem cell transplantation using in vivo alemtuzumab with or without CD52-positive malignancies.
Oshima K, Kanda Y, Nakahara F, Shoda E, Suzuki T, Imai Y, Watanabe T, Asai T, Izutsu K, Ogawa S, Motokura T, Chiba S, Kurokawa M. Oshima K, et al. Among authors: kanda y. Am J Hematol. 2006 Nov;81(11):875-9. doi: 10.1002/ajh.20694. Am J Hematol. 2006. PMID: 16862551 Free article.
1,359 results